Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ACLX

ACLX - Arcellx, Inc. Stock Price, Fair Value and News

62.52USD+0.28 (+0.45%)Market Closed

Market Summary

ACLX
USD62.52+0.28
Market Closed
0.45%

ACLX Alerts

  • 3 major insider sales recently.

ACLX Stock Price

View Fullscreen

ACLX RSI Chart

ACLX Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-66.18

Price/Sales (Trailing)

25.41

EV/EBITDA

-66.78

Price/Free Cashflow

-100.58

ACLX Price/Sales (Trailing)

ACLX Profitability

EBT Margin

-38.14%

Return on Equity

-10.18%

Return on Assets

-6.48%

Free Cashflow Yield

-0.99%

ACLX Fundamentals

ACLX Revenue

Revenue (TTM)

131.7M

Rev. Growth (Qtr)

-37.83%

ACLX Earnings

Earnings (TTM)

-50.5M

Earnings Growth (Yr)

73.68%

Earnings Growth (Qtr)

-136.27%

Breaking Down ACLX Revenue

Last 7 days

0.1%

Last 30 days

16.2%

Last 90 days

21.1%

Trailing 12 Months

85.3%

How does ACLX drawdown profile look like?

ACLX Financial Health

Current Ratio

5.46

ACLX Investor Care

Shares Dilution (1Y)

11.48%

Diluted EPS (TTM)

-1.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024131.7M000
2023000110.3M

Tracking the Latest Insider Buys and Sells of Arcellx, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 16, 2024
heery christopher
acquired
68,458
6.28
10,901
chief medical officer
Jul 16, 2024
heery christopher
sold
-711,854
65.3017
-10,901
chief medical officer
Jul 12, 2024
heery christopher
acquired
11,178
6.28
1,780
chief medical officer
Jul 12, 2024
heery christopher
sold
-107,175
60.2108
-1,780
chief medical officer
Jul 11, 2024
heery christopher
acquired
23,053
6.28
3,671
chief medical officer
Jul 11, 2024
heery christopher
sold
-220,302
60.0114
-3,671
chief medical officer
Jul 09, 2024
patel kavita
acquired
9,990
6.66
1,500
-
Jul 09, 2024
patel kavita
sold
-84,947
56.6314
-1,500
-
Jul 01, 2024
heery christopher
acquired
238,646
11.9323
20,000
chief medical officer
Jul 01, 2024
heery christopher
sold
-1,107,760
55.3881
-20,000
chief medical officer

1–10 of 50

Which funds bought or sold ACLX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
reduced
-13.9
-125,718
271,204
-%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
8.55
-4,396
27,319
-%
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-38.22
-360,830
346,980
0.05%
Jul 17, 2024
High Net Worth Advisory Group LLC
unchanged
-
-114,880
441,520
0.13%
Jul 17, 2024
KBC Group NV
added
51.8
10,000
56,000
-%
Jul 12, 2024
SG Americas Securities, LLC
sold off
-100
-852,000
-
-%
Jul 10, 2024
Simplicity Wealth,LLC
sold off
-100
-231,671
-
-%
Jul 10, 2024
CWM, LLC
added
190
1,000
2,000
-%
Jul 10, 2024
Fortitude Family Office, LLC
unchanged
-
-546
2,097
-%
Jul 09, 2024
HARBOR CAPITAL ADVISORS, INC.
added
8.34
-183,000
1,124,000
0.09%

1–10 of 46

Are Funds Buying or Selling ACLX?

Are funds buying ACLX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ACLX
No. of Funds

Unveiling Arcellx, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
fmr llc
-
0
SC 13G/A
Mar 25, 2024
sr one capital management, llc
4.44%
2,346,630
SC 13D/A
Feb 14, 2024
paradigm biocapital advisors lp
7.0%
3,658,624
SC 13G/A
Feb 14, 2024
perceptive advisors llc
8.8%
4,544,809
SC 13G/A
Feb 13, 2024
suvretta capital management, llc
5.0%
2,435,974
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G
Jan 29, 2024
blackrock inc.
6.2%
3,018,538
SC 13G
Dec 28, 2023
gilead sciences, inc.
12.9%
6,720,803
SC 13G/A
Dec 18, 2023
sr one capital management, llc
6.46%
3,146,630
SC 13D/A
Jul 21, 2023
paradigm biocapital advisors lp
5.05%
2,422,700
SC 13G

Recent SEC filings of Arcellx, Inc.

View All Filings
Date Filed Form Type Document
Jul 18, 2024
4
Insider Trading
Jul 12, 2024
4
Insider Trading
Jul 11, 2024
144
Notice of Insider Sale Intent
Jul 11, 2024
4
Insider Trading
Jul 09, 2024
144
Notice of Insider Sale Intent
Jul 03, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 28, 2024
4
Insider Trading
Jun 27, 2024
144
Notice of Insider Sale Intent
Jun 26, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Arcellx, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Arcellx, Inc. News

Latest updates
Defense World17 hours ago
American Banking and Market News22 hours ago
American Banking and Market News17 Jul 202406:27 am

Arcellx, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q1
Revenue-37.8%39,256,00063,148,00014,957,00014,302,00017,912,000
Operating Expenses14.4%55,066,00048,149,00059,819,00043,862,00048,369,000
  S&GA Expenses17.5%22,748,00019,365,50016,012,00015,535,00015,437,000
  R&D Expenses12.3%32,318,00028,783,50043,807,00028,327,00032,932,000
EBITDA Margin41.1%-0.36-0.62---
Income Taxes-100.0%-631,000-6,000-300,000329,000
Earnings Before Taxes-135.2%-7,198,00020,466,000-39,342,000-24,136,000-27,015,000
EBT Margin39.9%-0.38-0.63---
Net Income-136.3%-7,198,00019,844,000-39,336,000-23,854,000-27,344,000
Net Income Margin40.1%-0.38-0.64---
Free Cashflow-172.4%-38,339,00052,955,000-18,029,000-29,843,000181,062,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42020Q4
Assets-5.5%78082561462462331433737524712958.00
  Current Assets-17.8%58971649155857126729032522411349.00
    Cash Equivalents-60.8%15539512630427567.0057.0016512731.0047.00
  Net PPE5.2%45.0043.0038.0022.0014.0011.0010.0010.0010.0010.005.00
Liabilities-16.7%28334034833031910910151.0019.0017.007.00
  Current Liabilities-8.7%10811817315616657.0045.0024.0014.0015.005.00
Shareholder's Equity2.3%497485266294304205236324228--
  Retained Earnings-1.8%-396-389-409-370-346-318-279-186-156-130-65.14
  Additional Paid-In Capital2.2%8948746756646505245165113849.001.00
Shares Outstanding1.9%53.0052.0049.0048.0047.0044.0044.0037.0021.00-0.00
Float----1,300---453---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Cashflow From Operations-154.8%-31.9158.00-10.10-22.61182-27.52-16.65-22.55-32.59-21.55-12.22-10.96-9.51-
  Share Based Compensation39.8%15.0011.0011.0010.0010.006.005.006.004.003.002.001.001.00-
Cashflow From Investing-1084.0%-20621.00-16051.00-66.7734.00-81.42-59.23-10.64-17.66-61.07-0.18-1.07-
Cashflow From Financing-101.6%-2.98189-4.990.0095.001.00-9.711211400.00-0.4737.0082.00-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ACLX Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Collaboration revenue from related party$ 39,256$ 17,912
Operating expenses:  
Research and development32,31832,932
General and administrative22,74815,437
Total operating expenses55,06648,369
Loss from operations(15,810)(30,457)
Other income (expense):  
Interest income, net9,2004,468
Interest expense(588)(1,026)
Total other income, net8,6123,442
Loss before income taxes(7,198)(27,015)
Income tax expense0329
Net loss(7,198)(27,344)
Other comprehensive loss:  
Unrealized gain (loss) on marketable securities(1,059)307
Comprehensive loss$ (8,257)$ (27,037)
Net loss per share attributable to common stockholders - basic$ (0.14)$ (0.58)
Net loss per share attributable to common stockholders - diluted$ (0.14)$ (0.58)
Weighted-average common shares outstanding - basic52,757,97346,769,380
Weighted-average common shares outstanding - diluted52,757,97346,769,380

ACLX Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets, Current [Abstract]  
Cash and cash equivalents$ 154,574$ 394,583
Marketable securities419,345307,434
Restricted cash, current2081,903
Prepaid expenses and other current assets14,60612,443
Total current assets588,733716,363
Restricted cash, non-current2,4182,418
Marketable securities non current117,10227,168
Property and equipment, net44,93042,728
Operating lease right-of-use assets24,19627,099
Prepaid research and development expenses and other long-term assets2,3169,356
Total assets779,695825,132
Current liabilities:  
Accounts payable3,0992,619
Accrued liabilities33,93318,302
Operating lease liabilities, current portion7,1467,501
Finance lease liabilities, current portion32,53139,283
Contract liability to related party31,19250,533
Total current liabilities107,901118,238
Operating lease liabilities, net of current portion47,68550,841
Contract liability, net of current portion to related party112,068170,673
Other non-current liabilities15,468 
Total liabilities283,122339,752
Commitments and contingencies (Note 7)
Stockholders' equity  
Common stock, par value of $0.001 per share; 1,000,000,000 shares authorized and 53,287,990 shares issued and outstanding as of March 31, 2024; 1,000,000,000 shares authorized and 52,280,077 shares issued and outstanding as of December 31, 20235352
Additional paid-in capital893,710874,261
Accumulated other comprehensive income (loss)(512)547
Accumulated Deficit(396,678)(389,480)
Total stockholders' equity496,573485,380
Total liabilities and stockholders' equity$ 779,695$ 825,132
ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
 CEO
 WEBSITEhttps://arcellx.com
 INDUSTRYBiotechnology
 EMPLOYEES98

Arcellx, Inc. Frequently Asked Questions


What is the ticker symbol for Arcellx, Inc.? What does ACLX stand for in stocks?

ACLX is the stock ticker symbol of Arcellx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arcellx, Inc. (ACLX)?

As of Fri Jul 19 2024, market cap of Arcellx, Inc. is 3.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers.

What is the fair value of ACLX stock?

You can check ACLX's fair value in chart for subscribers. The fair value of Arcellx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arcellx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arcellx, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACLX is over valued or under valued. Whether Arcellx, Inc. is cheap or expensive depends on the assumptions which impact Arcellx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACLX.

What is Arcellx, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, ACLX's PE ratio (Price to Earnings) is -66.18 and Price to Sales (PS) ratio is 25.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACLX PE ratio will change depending on the future growth rate expectations of investors.